BR112018015481A2 - processo para preparar um complexo de ciclodextrina e ingrediente farmacêutico ativo - Google Patents

processo para preparar um complexo de ciclodextrina e ingrediente farmacêutico ativo

Info

Publication number
BR112018015481A2
BR112018015481A2 BR112018015481-4A BR112018015481A BR112018015481A2 BR 112018015481 A2 BR112018015481 A2 BR 112018015481A2 BR 112018015481 A BR112018015481 A BR 112018015481A BR 112018015481 A2 BR112018015481 A2 BR 112018015481A2
Authority
BR
Brazil
Prior art keywords
solution
preparing
active pharmaceutical
pharmaceutical ingredient
cyclodextrin
Prior art date
Application number
BR112018015481-4A
Other languages
English (en)
Other versions
BR112018015481B1 (pt
Inventor
Lisboa Hugo
Temtem Márcio
Vicente João
Santos Filipa
Original Assignee
Hovione Scientia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Scientia Limited filed Critical Hovione Scientia Limited
Publication of BR112018015481A2 publication Critical patent/BR112018015481A2/pt
Publication of BR112018015481B1 publication Critical patent/BR112018015481B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

trata-se de um processo de complexação entre uma ciclodextrina e ingredientes farmacêuticos ativos, e compreende um processo para preparar um complexo de pelo menos uma ciclodextrina e pelo menos um ingrediente farmacêutico ativo que compreende as etapas de: a. preparar uma primeira solução (solução a) que compreende pelo menos uma ciclodextrina e pelo menos um solvente; b. preparar uma segunda solução (solução b) que compreende pelo menos um api dissolvido, parcialmente dissolvido ou suspenso; c. misturar a dita solução a e a dita solução b por meio de um sistema de microfluidização para produzir uma solução e/ou suspensão de pelo menos um do dito complexo; d. isolar a dita solução e/ou suspensão e/ou, opcionalmente, secar a mesma; e e. coletar opcionalmente uma forma em pó do complexo. o processo descrito tem alta produtividade com rendimentos maiores de complexação em menos tempo que métodos da técnica anterior. os complexos obtidos pela invenção são caracterizados por terem dissolução e/ou biodisponibilidade aprimoradas do ingrediente farmacêutico ativo em fluidos corporais.
BR112018015481-4A 2016-01-28 2017-01-27 Processo para preparar um complexo de ciclodextrina e ingrediente farmacêutico ativo BR112018015481B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT109117 2016-01-28
PT10911716A PT109117B (pt) 2016-01-28 2016-01-28 Complexação de ingredientes ativos farmacêuticos
PCT/GB2017/050210 WO2017129988A1 (en) 2016-01-28 2017-01-27 Continuous complexation of active pharmaceutical ingredients

Publications (2)

Publication Number Publication Date
BR112018015481A2 true BR112018015481A2 (pt) 2018-12-18
BR112018015481B1 BR112018015481B1 (pt) 2024-04-09

Family

ID=

Also Published As

Publication number Publication date
CN108778338A (zh) 2018-11-09
PT109117A (pt) 2017-07-28
EP3400017B1 (en) 2020-02-19
JP7038057B2 (ja) 2022-03-17
AU2017211520B2 (en) 2022-01-27
JP2019507127A (ja) 2019-03-14
CN108778338B (zh) 2022-04-01
EP3400017A1 (en) 2018-11-14
CA3011820C (en) 2023-12-19
CA3011820A1 (en) 2017-08-03
PT109117B (pt) 2019-02-01
US20190060486A1 (en) 2019-02-28
IL260766B (en) 2020-11-30
US11759529B2 (en) 2023-09-19
PL3400017T3 (pl) 2020-07-13
HUE048601T2 (hu) 2020-07-28
AU2017211520A1 (en) 2018-08-16
WO2017129988A1 (en) 2017-08-03
DK3400017T3 (da) 2020-05-18

Similar Documents

Publication Publication Date Title
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CY1121776T1 (el) C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων
EA201892173A1 (ru) Фармацевтический состав палбоциклиба и способ его получения
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EP3928800A3 (en) Dry powder composition comprising long-chain rna
BR112018013218A2 (pt) derivado de acrilanilida, método de preparação e aplicação do mesmo na farmácia
CY1120715T1 (el) Παραγωγα ετεροαρυλιου βουτανικου οξεος ως αναστολεις lta4h
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
MX2018001145A (es) Métodos para la preparación de ácidos biliares y derivados de los mismos.
CY1123984T1 (el) Συνθεσεις και μεθοδοι για λυοφιλες μορφες νανοσωματιδιων
CL2017001592A1 (es) Complejos radiofarmacéuticos.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CR20210294A (es) Compuestos heteroaromáticos como inhibidores de vanina
JOP20210034A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
BR112018076389A2 (pt) composto, método para preparação de um composto, e, composição farmacêutica.
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
PH12016502359B1 (en) Lobaplatin crystals, preparation methods and pharmaceutical applications
MX2015016957A (es) Sintesis de dicarbamatos a partir de productos de la reduccion de 2-hidroximetil-5-furfural (hmf) y sus derivados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2017, OBSERVADAS AS CONDICOES LEGAIS